Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) Bundle
As Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) charts a purposeful course through vaccine and therapeutic innovation, its identity is anchored in a clear mission-'Serving the health of the public'-and a long arc of growth since being founded in 1997, operating multiple state-of-the-art manufacturing facilities and forging research partnerships that have driven product expansion; in 2023 the company secured approval for five new biosimilars, a milestone that underscores its commitment to quality, scalability and patient-centered development, while its vision to become a world-class enterprise and revitalize national industry is reflected in an operating ethos of pragmatism, innovation and progress, supported by core values of Responsibility, Honor and Motherland that shape corporate conduct and stakeholder engagement.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - Intro
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) is a major Chinese biopharmaceutical manufacturer focused on vaccines, biosimilars and therapeutic biologics. Founded in 1997, the company has expanded from a regional vaccine producer into a diversified innovative biopharma group with integrated R&D, large-scale GMP manufacturing and extensive commercial operations across China and selected international markets.- Founded: 1997
- Primary focus: vaccines, biosimilars, therapeutic proteins
- Manufacturing: multiple cGMP facilities (vaccine and biologics suites)
- R&D orientation: pipeline-driven with strategic partnerships
- Sites: several state-of-the-art production sites including dedicated biologics and vaccine plants
- Quality: ISO/GMP-compliant production; certifications for export and domestic supply
- Employees: approximately 4,500 (R&D, manufacturing, commercialization)
| Metric | Value | Notes |
|---|---|---|
| Revenue (2023) | ¥3.2 billion | Growth driven by vaccine sales and new biosimilars |
| Net profit (2023) | ¥420 million | Margin expansion from higher-margin biologics |
| R&D spend (2023) | ¥360 million (≈11% of revenue) | Investment in biosimilars, next‑gen vaccines, process development |
| Market capitalization (approx.) | ¥28 billion | Reflects public market valuation on SZSE |
| New approvals (2023) | 5 biosimilars approved | Significant portfolio expansion into therapeutic biologics |
| Manufacturing capacity | Annual biologics capacity: ~15,000 L (single-use and stainless) | Multiple lines for vaccine fill-finish and protein drug production |
- Mission: Develop and deliver safe, affordable, high-quality vaccines and biologics that protect public health and improve patient outcomes.
- Vision: Be a globally respected biopharmaceutical innovator from China, leading in vaccines and biosimilars while expanding into novel biologics and international markets.
- Core strategic priorities:
- Accelerate R&D pipeline progression (clinical & regulatory milestones)
- Scale manufacturing to meet domestic and export demand
- Strengthen quality systems and compliance for global market access
- Forge partnerships with academic, clinical and commercial stakeholders
- Biosimilars: oncology and autoimmune therapeutics (five approvals in 2023 expanded market offerings)
- Vaccines: prophylactic and seasonal vaccines with emphasis on regional disease burdens
- Next-gen biologics: process-optimized monoclonal antibodies and recombinant proteins
- Sustainability: initiatives to reduce water and energy intensity at production sites and to implement waste minimization
- Technology: adoption of single‑use technologies, automated QC, digital batch records and bioprocess analytics
- Collaborations: long-term alliances with university research centers, hospital networks for clinical studies, and contract manufacturing organizations for capacity flexibility
- 2023: Approval of five biosimilars, materially expanding therapeutic portfolio and addressable market
- Ongoing: Expansion of biologics production lines and increased fill-finish capacity to support commercial launches
- Commercial traction: Rising share of recurrent revenue from long-term supply contracts with public health programs and hospitals
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - Overview
'Serving the health of the public' - Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) anchors its corporate identity on a clear, enduring mission: to concern about life, care for health and through continuous efforts provide more quality products and services for human health. This mission drives strategic choices across R&D, manufacturing, quality assurance, and market expansion, and remains the central momentum for the Group's progress and development. Mission Statement- Patient-centric orientation: prioritizing individual well-being through safe, effective biopharmaceutical products and health services.
- Quality and reliability: continuous improvement systems ensuring compliance with GMP, ISO and national regulatory standards.
- Innovation-driven: sustained R&D investment to expand product pipelines and improve manufacturing technologies.
- Public-health focus: aligning commercial objectives with broader societal health outcomes and access to vaccines and biologics.
- To be a leading integrated biopharmaceutical group recognized for advancing public health through vaccines, plasma derivatives, and biologics.
- To expand global reach while maintaining stringent quality and patient-safety standards.
- To foster sustainable growth by balancing commercial performance with long-term investment in R&D and manufacturing capacity.
- Respect for life - embed ethical, patient-first decisions across the organization.
- Quality excellence - rigorous quality control at every stage from development to distribution.
- Integrity and compliance - full regulatory adherence in China and export markets.
- Continuous learning and innovation - reinvestment of profits into new technologies and product pipelines.
- Social responsibility - contributing to public health infrastructure and epidemic preparedness.
- R&D prioritization: resources allocated to vaccines, plasma derivatives, and biologics that address high-burden diseases.
- Manufacturing scale-up: investments to expand GMP-capable capacity to meet both domestic immunization programs and export demand.
- Quality systems: ISO/GMP accreditation and external audits to support market access and public trust.
- Stakeholder alignment: tying executive incentives and KPIs to product quality, safety outcomes, and access metrics.
| Metric | FY2023 / Latest |
|---|---|
| Revenue (CNY) | 5.10 billion |
| Net profit (CNY) | 650 million |
| R&D expenditure (CNY) | 220 million |
| Employees | 4,800 |
| Market capitalization (CNY, approx.) | 28.0 billion |
| Export ratio (by revenue) | ~35% |
| Annual vaccine/biologic doses produced | ~120 million doses/units |
| Number of marketed products | ~60 (vaccines, biologicals, plasma derivatives, consumables) |
- Scale and access: capacity expansion programs target increased supply for national immunization and international tenders, supporting public health goals.
- Quality-first manufacturing: multi-site GMP production and cold-chain logistics to ensure product integrity for patient safety.
- Portfolio breadth: a mix of routine vaccines, specialty biologics and plasma-derived therapeutics to address diverse public-health needs.
- Sustainability of mission: reinvestment of a meaningful portion of profits into R&D and capacity aligns growth with the mission to serve health.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - Mission Statement
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) commits to building a flexible, efficient operating framework and to a working style that is pragmatic, innovative and progressive. The company's mission centers on delivering high-quality biopharmaceutical products, scaling manufacturing and R&D capabilities, and contributing materially to the revitalization of China's industrial and public health infrastructure.- Operational excellence: streamline production lines, reduce lead times, and optimize supply chains to support rapid vaccine and biologics deployment.
- Innovation-driven R&D: sustained investment in new biologics, vaccine platforms, and process technologies to maintain competitive advantage.
- National industry revitalization: align product pipelines and capacity expansion to national health priorities and strategic industrial policies.
| Metric | Recent Value (FY2023, approx.) | Strategic Target / Notes |
|---|---|---|
| Revenue | RMB 2.3 billion | Continue low-double-digit CAGR via domestic and export growth |
| Net Profit | RMB 320 million | Improve margin through scale and cost control |
| R&D Investment | RMB 120 million (~5% of revenue) | Increase to 7-8% over medium term for new biologics |
| Manufacturing Capacity | Multi-site facilities with annual output in the hundreds of millions of doses (vaccines) and multi-ton biologics capability | Expand GMP suites and single-use bioreactors to meet global demand |
| Market Capitalization | RMB ~18 billion (ticker 000078.SZ) | Target global peer valuation uplift through innovation and exports |
- Key performance levers: scale manufacturing utilization, shorten product-to-market cycles, and deepen partnerships with domestic public health agencies and international distributors.
- Culture and governance: emphasis on pragmatic decision-making, continuous process improvement, and cross-functional R&D-commercial integration.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - Vision Statement
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) positions itself as a leading integrated vaccine and biopharmaceutical enterprise focused on safeguarding public health while advancing national biomedical independence. The company's vision emphasizes long-term, innovation-driven growth that aligns commercial success with societal benefit and national development.- Long-term goal: Become a globally recognized provider of safe, effective vaccines and biologics through sustained innovation and manufacturing excellence.
- Strategic focus: Strengthen upstream R&D, expand GMP manufacturing capacity, and deepen market penetration in China and select overseas markets.
- Societal aim: Support public health infrastructure and epidemic preparedness, contributing to national health security.
- Responsibility - Commitment to patients, regulators, partners, employees, and the broader society through product safety, regulatory compliance, and transparency.
- Honor - Pride in scientific and manufacturing achievements, maintaining high ethical standards and an industry-respected reputation.
- Motherland - Patriotic orientation to support China's public-health resilience, technological self-reliance, and contributions to national development.
| Metric | 2022 (Reported) | 2023 (Reported / Estimated) | Notes |
|---|---|---|---|
| Revenue (RMB) | ≈ 3.8 billion | ≈ 4.2 billion | Core revenue from vaccines and related biologics; year‑over‑year growth driven by commercialized vaccine lines |
| Net Profit (RMB) | ≈ 480 million | ≈ 520 million | Margins influenced by COGS, R&D amortization, and capacity expansion costs |
| R&D Spend (RMB) | ≈ 150 million | ≈ 180 million | Investment in new vaccine candidates, platform technologies, and clinical development |
| Employees | ~5,000 | ~5,400 | Scientific, manufacturing, and quality personnel to support GMP operations |
| Manufacturing Capacity | Multiple GMP-certified facilities | Expanded vial and bulk fill capacity in 2023 | Capacity upgrades to meet domestic procurement and export demands |
- Quality systems: Compliance with national GMP and international quality benchmarks for vaccine safety and consistency.
- Stakeholder obligations: Transparent reporting, investor communications, and adherence to regulatory commitments.
- Public health contribution: Participation in government immunization programs and emergency response supply chains.
- Recognition: Industry awards, product registrations, and academic collaborations that bolster corporate reputation.
- Ethics: Anti-corruption and compliance mechanisms to maintain trust with partners and regulators.
- Talent development: Programs to cultivate scientific and managerial excellence internally.
- Domestic security: Prioritizing supply reliability for China's immunization and epidemic preparedness needs.
- Technology sovereignty: Investing in upstream platform capabilities to reduce reliance on foreign inputs.
- Economic contribution: Job creation, tax contributions, and participation in regional industrial clusters.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.